Selective phosphodiesterase type 5 (PDE5) inhibitor of the pyrrolopyrimidinone structural class
A second-generation pyrrolopyrimidinone PDE5 inhibitor developed by SK Chemicals in South Korea for erectile dysfunction, distinguished from first-generation agents by approximately 10-fold higher PDE5 affinity, superior isoenzyme selectivity, and an emerging multimodal research profile in Alzheimer’s disease through cGMP/PKG/CREB signaling, autophagy enhancement, and neuroinflammatory modulation.
Abstract
Mirodenafil (SK3530) is a potent, selective, and reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) belonging to the pyrrolopyrimidinone structural class. The compound inhibits PDE5 with an IC50 of 0.34 nmol/L, approximately 10-fold more potent than sildenafil (IC50 3.5 nmol/L), and exhibits selectivity ratios of approximately 48,235-fold over PDE1, 254,000-fold over PDE3, and greater than 10,000-fold over PDE11. Pharmacokinetically, mirodenafil is rapidly absorbed after oral administration with a time to maximum plasma concentration of 0.67 to 1.5 hours, an elimination half-life of 1.32 to 3.0 hours, oral bioavailability of 24 to 43 percent for the parent compound, and approximately 97 percent plasma protein binding. Metabolism is predominantly hepatic through CYP3A4-mediated N-dealkylation to the active metabolite SK-3541, which retains approximately one-tenth of the PDE5 inhibitory activity of the parent compound. Clinical efficacy in erectile dysfunction has been demonstrated in multiple randomized, double-blind, placebo-controlled trials totaling more than 700 patients across general, diabetic, and hypertensive populations, with improvements in the International Index of Erectile Function erectile function domain score of 7 to 12 points over placebo. Adverse events are predominantly mild to moderate, with flushing (3.3 to 24.1 percent) and headache (1.8 to 14.8 percent) as the most common; no visual disturbances or myalgia have been reported in published trials. Beyond erectile dysfunction, mirodenafil (designated AR1001 by licensee AriBio) has entered clinical development for Alzheimer’s disease on the basis of preclinical evidence demonstrating multimodal neuroprotective activity: activation of the cGMP/PKG/CREB signaling pathway, enhancement of autophagy-lysosome clearance of amyloid-beta and phosphorylated tau, suppression of neuroinflammation, and improvement of mitochondrial function. The global Phase 3 POLARIS-AD trial, enrolling approximately 1,150 participants with early Alzheimer’s disease across 200 sites under FDA, EMA, and MHRA authorization, is currently underway with a primary endpoint of change in Clinical Dementia Rating Sum of Boxes at 52 weeks. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.